Quantcast

Latest Galderma Stories

2014-07-15 08:28:50

TORONTO, July 15, 2014 /CNW/ - The Odette Cancer Centre at Sunnybrook Health Sciences Centre in conjunction with Galderma Canada are pleased to announce that Metvix PDT (Photodynamic Therapy), is now available at the Odette Cancer Centre in Toronto as an additional treatment option for patients with NMSC (non-melanoma skin cancer). For eligible patients the positive impact of Metvix PDT cannot be overestimated in pre-cancerous AK (Actinic Keratoses) and superficial BCC (Basal Cell...

2014-07-10 23:02:13

In-demand research report “OpportunityAnalyzer: Acne Vulgaris - Opportunity Analysis and Forecasts to 2018” prepared by GlobalData is now available at MarketPublishers.com. According to the study, the six major pharma markets are expected to post an around 4% CAGR through 2018. London, UK (PRWEB) July 10, 2014 Notwithstanding its considerable patient pool across the US and 5EU acne market has remained stagnant over the past few decades, with no new drugs coming into the arena. The...

2014-07-10 12:30:26

Expansion Completes Galderma's Global Skin Health Footprint FORT WORTH, Texas, July 10, 2014 /PRNewswire/ -- Galderma S.A. (Galderma) announced that it has gained full rights to distribute Restylane®, Perlane®, Emervel®, Sculptra® and Dysport® from Valeant Pharmaceuticals International, Inc. The expansion into aesthetic and corrective dermatology in the U.S. and Canada completes Galderma's global skin health footprint and extends its leadership in aesthetic medicine worldwide....

2014-07-10 12:29:53

LAVAL, Quebec, July 10, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced it has completed the sale to Galderma of all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport owned or held by Valeant for $1.4 billion in cash, pursuant to the previously announced agreement with Nestle S.A, which recently completed its acquisition of Galderma. "We are pleased to complete the divestiture of our products to a company that is...

2014-06-18 08:28:09

-- Latest psychological research reveals rosacea redness creates negative first impressions putting sufferers at a disadvantage -- Rosacea remains under-diagnosed, yet diagnosis is a critical first step to better symptom control THORNHILL, ON, June 18 2014 /CNW/ - Sex and the City actress Cynthia Nixon today spoke out about her experience of rosacea in support of 'Act on Red', a new global disease awareness program urging fellow sufferers to seek help for their...

2014-06-13 20:21:55

LAVAL, Quebec, June 13, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE: VRX) (TSX: VRX) today announced that Ryan Weldon, Valeant's Executive Vice President and Company Group Chairman, will be leaving the Company following the divestiture of all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport owned or held by Valeant to Nestlé S.A. Nestle expects to complete its acquisition of Galderma S.A. in July and would expect to operate the...

2014-06-11 23:07:38

ReportsnReports.com adds “OpportunityAnalyzer: Acne Vulgaris – Opportunity Analysis and Forecasts to 2018” to its store. Order a purchase copy of this report @ http://www.reportsnreports.com/Purchase.aspx?name=288017. Dallas, Texas (PRWEB) June 11, 2014 Despite its considerable patient population, the acne market has been overlooked and remained stagnant for the last decade. There has been a lack of research efforts due to the perception of a poor return on investment for topical...

2014-05-28 12:32:31

- Galderma positioned to commercialize Restylane®, Perlane®, Emervel®, Sculptra®, Dysport® in the U.S. and Canada FORT WORTH, Texas, May 28, 2014 /PRNewswire/ -- Galderma Laboratories, L.P. ("Galderma") announced today that Nestle S.A., Switzerland, one of Galderma's shareholders, has entered into an agreement with Valeant Pharmaceuticals International, Inc. and related entities ("Valeant"), through which Galderma will become the distributor of several key products in...

2014-05-28 00:21:31

LAVAL, Quebec, May 28, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it has entered into an agreement with Nestle S.A. to sell all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport owned or held by Valeant for $1.4 billion in cash. Nestle expects to complete its acquisition of Galderma S.A. in July and would expect to operate the acquired assets through Galderma. The transaction is subject to customary closing...

2014-05-22 16:26:31

Health Canada Approves The First and Only Topical Treatment Indicated for the Persistent Facial Erythema of Rosacea THORNHILL, ON, May 21, 2014 /CNW/ - Galderma Canada Inc., today announced that ONRELTEA(TM) topical gel (Brimonidine gel 0.33%) has been approved by Health Canada and is now available for Canadian patients 18 and older to treat the facial erythema (redness) of rosacea. ONRELTEA is the first and only Health Canada-approved topical prescription specifically designed to...


Word of the Day
siliqua
  • A Roman unit of weight, 1⁄1728 of a pound.
  • A weight of four grains used in weighing gold and precious stones; a carat.
  • In anatomy, a formation suggesting a husk or pod.
  • The lowest unit in the Roman coinage, the twenty-fourth part of a solidus.
  • A coin of base silver of the Gothic and Lombard kings of Italy.
'Siliqua' comes from a Latin word meaning 'a pod.'
Related